CAR-T Therapy in China: What Is Labelled, What It Costs, Who Qualifies
CAR-T in China is labelled for selected blood cancers and, since 22 June 2026, satri-cel for CLDN18.2-positive, HER2-negative advanced gastric/GEJ cancer after two lines. Lancet phase 2: PFS 3.25 vs 1.77 months. CRS is expected. We do not manufacture cells. Send the file. About 24 hours. No obligation to book.
Average reply: 24 hoursNo obligation to book
Label firstCD19 BCMA satri-cel
PFS 3.25 vs 1.77Lancet phase 2
CRS expectednot a rare footnote
Quick answer
CAR-T in China is labelled for selected blood cancers (CD19, BCMA) and, since 22 June 2026, for one solid-tumour door: satri-cel in CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma after two prior lines. It is collection, engineering, chemo, reinfusion and a toxicity watch. CRS is a class risk. Navigator bands: public blood-cancer CAR-T sometimes from the mid five-figure USD range; private packages often about USD 70,000-90,000; satri-cel product cited around RMB 990,000 before stay and ICU. We do not manufacture cells. Send the file. About 24 hours. No obligation to book.
What is actually approved — and what is not
CAR-T cell therapy in China is available through selected licensed hospitals and disease-specific hematology/oncology programs. It is not one uniform treatment: eligibility depends on the exact cancer type, target antigen, prior therapies, disease status, organ function and the product or clinical protocol available at the hospital.
| Product / class | Typical use discussed | Status for planning |
|---|---|---|
| CD19 CAR-T | Selected B-cell leukaemias and lymphomas | NMPA-approved at designated centres |
| BCMA CAR-T | Selected relapsed or refractory myeloma | NMPA-approved at designated centres |
| Satri-cel | Claudin18.2+ HER2- advanced gastric / GEJ, at least 2 prior lines | Narrow 2026 solid-tumour approval — not all gastric cancer |
| TIL / TCR-T / other solid-tumour CAR-T | Selected trial cohorts only | Investigational — no walk-in product |
Satri-cel screen — all of these, not one
If any box is missing from the file, do not treat a travel quote as eligibility.
Claudin18.2-positive tumour status on a real report
HER2-negative disease
Advanced gastric or GEJ adenocarcinoma
At least two prior systemic lines
Indicative CAR-T cost bands
Public navigation figures for planning only. Demand an itemised hospital estimate (product, lymphodepletion, bed days, ICU, drugs).
The cost of CAR-T cell therapy in China can vary substantially because the total pathway may include eligibility testing, cell collection, the CAR-T product, lymphodepleting chemotherapy, hospitalization, monitoring, management of complications and follow-up. A hospital-specific written estimate is more meaningful than a generic CAR-T price.
Approved CAR-T treatment and CAR-T clinical trials are not the same access route. A trial may use a different product, indication or eligibility protocol, and international-patient participation must be confirmed with the study team before travel.
| Setting | Planning range |
|---|---|
| Selected public-hospital blood-cancer pathways | from about USD 25,000 |
| Private-hospital blood-cancer CAR-T | about USD 70,000-90,000 |
| Complex commercial packages | up to about USD 170,000-200,000 |
| Satri-cel product only | about RMB 990,000 / USD 146,000 |
Centres often compared: Peking University Cancer Hospital, Ruijin, CAMS/NCC, Fudan. · Cancer hub · Cost drivers
What actually changes the plan
📋
Antigen and line review first
CD19, BCMA or Claudin18.2/HER2 status, prior lines, organ function and infections — before anyone discusses a travel date.
🏥
Designated CAR-T centres only
PKU Cancer, Ruijin, CAMS/NCC, Fudan and other licensed sites. No unnamed 'cell clinic' referrals.
✈️
Itemised cost and stay
Product vs bed days vs ICU vs drugs. Invitation letter and interpreter after a centre will screen the file.
What this page helps you decide
✅
Approved vs trial on the page
Blood-cancer CAR-T, satri-cel's narrow gastric niche, and investigational TIL/TCR-T are labelled separately.
💬
Cost as a list, not a teaser
Public vs private bands, satri-cel product-only figure, and what must appear on a hospital estimate.
🌍
Toxicity is part of the plan
CRS and neurotoxicity mean you stay near the centre. We do not sell a tourist add-on around infusion week.
Evidence table
NMPA labels vs Lancet satri-cel PFS/toxicity vs navigator cost bands.
| Source | What it says | Relevance to patients |
|---|---|---|
| NMPA CD19 / BCMA labels (2021-) | Selected B-cell leukaemia/lymphoma; r/r myeloma at designated centres | Diagnosis and licence have to match. |
| NMPA satri-cel (22 Jun 2026) | CLDN18.2+, HER2-, G/GEJA, ≥2 lines | First solid-tumour CAR-T label. Not all gastric cancer. |
| Lancet phase 2 (2025-26) | PFS 3.25 vs 1.77 months; G≥3 AE 99%; CRS common | Expect toxicity. Do not read as a cure rate. |
| Navigator cost bands (current) | Public mid five figures USD; private ~70-90k; satri-cel ~RMB 990k product | Not our invoice. ICU changes the total. |
Who this page is for
Relapsed blood cancers
B-cell leukaemia, lymphoma or myeloma after prior lines, where CD19 or BCMA CAR-T may be commercially available.
Gastric / GEJ with Claudin18.2 data
Need a satri-cel screen against the actual label — not a generic solid-tumour CAR-T advertisement.
Families comparing overseas quotes
Have a US or EU CAR-T number and need an honest China range plus the list of exclusions.
What you can actually book
An eligibility screen at designated rooms (PKU Cancer, Ruijin, CAMS/NCC, Fudan and others). For satri-cel the file needs CLDN18.2, HER2-negative, gastric/GEJ adenocarcinoma, two prior lines. Related: stomach, cost, centres.
The CAR-T products approved in China, one by one
Nine CAR-T products are approved in China. Each one is approved for a specific disease and a specific situation, usually after several lines of treatment have stopped working. The table shows what each product is used for, whether it is used in the USA, and what to check in your records.
| Product | Disease | When it is used in China | Used in the USA? | What to check in your records |
|---|---|---|---|---|
| Axicabtagene (Yescarta) | Large B-cell lymphoma in adults | When first chemoimmunotherapy did not work or the disease came back within 12 months of it. Also after two or more lines of treatment. | Yes | Exact lymphoma type from the biopsy, every line of treatment with dates, when the relapse happened |
| Relmacabtagene | Large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma in adults | After two or more lines of treatment. For follicular lymphoma: if it did not respond or came back within 24 months. For mantle cell lymphoma: if one of the lines included a BTK inhibitor. | No | Lymphoma type, the names of all drugs by line, the response to each line |
| Inaticabtagene | B-cell acute lymphoblastic leukaemia in adults, and large B-cell lymphoma | Leukaemia: when it has come back or did not respond. Lymphoma: after two or more lines of treatment. | No | Confirmed B-cell disease type, lines of treatment and the response to each |
| Puzolcabtagene | B-cell acute lymphoblastic leukaemia in children and young people aged 3 to 21 | When it has come back or did not respond. If it came back more than 12 months after the first remission, repeat chemotherapy is needed first. | No | Age, CD19 on the leukaemia cells, dates of remission and relapse |
| Ranicabtagene | Large B-cell lymphoma in adults, including lymphoma that developed from follicular lymphoma | After two or more lines of treatment | No | Lymphoma type from the biopsy, number of treatment lines |
| Equecabtagene | Multiple myeloma in adults | When the disease progresses after at least three lines, including a proteasome inhibitor and an immunomodulatory drug | No | The names of all drugs by line and the response to each |
| Zevorcabtagene | Multiple myeloma in adults | Same conditions: progression after at least three lines, including a proteasome inhibitor and an immunomodulatory drug | No | The names of all drugs by line and the response to each |
| Ciltacabtagene (Carvykti) | Multiple myeloma in adults | When the disease progresses after at least three lines, including a proteasome inhibitor and an immunomodulatory drug | Yes. In the USA it is used earlier: after one line, if the myeloma no longer responds to lenalidomide. | The names of all drugs by line, whether lenalidomide was used and how the myeloma responded |
| Satricabtagene | Advanced adenocarcinoma of the stomach or the junction of the stomach and oesophagus | When the tumour is Claudin18.2-positive and HER2-negative, and at least two lines of treatment have not worked | No | Tumour tests for Claudin18.2 and HER2, list of treatment lines |
Kymriah, Tecartus, Breyanzi, Abecma and Aucatzyl are also used in the USA. They are not among the products approved in China. Approval does not mean a product suits everyone with that diagnosis: the centre decides after reading the records.
How long it takes, and why you stay near the centre
- From collecting the cells to giving them back usually takes about 3 to 5 weeks.
- Before the infusion there is a short course of chemotherapy, usually cyclophosphamide and fludarabine.
- Under US rules, the patient is checked every day for the first week after the infusion, stays near a medical centre for at least two weeks, and does not drive for two weeks.
- Hepatitis B and C and HIV are tested before the cells are collected: after CAR-T that acts on B cells, hepatitis B can flare up again.
Risks to know about in advance
Blood
Low blood counts for several weeks
After the chemotherapy and the CAR-T infusion, blood counts can stay low for several weeks. That is why blood tests are checked regularly.
Immunity
Infections and low antibodies
Infections are one of the most common problems. CAR-T also destroys healthy B cells, which make antibodies, so antibody levels are checked and topped up if needed.
Later risk
A new T-cell cancer
T-cell cancers have been reported after CD19- or BCMA-directed CAR-T. They can appear within weeks and can be fatal. That is why patients are followed for life after treatment.
If no approved product fits: clinical trials
China has a public, government-run register of clinical trials that can be searched by diagnosis or drug name. Only people who meet the conditions of a specific trial can join it. Whether a trial accepts patients from abroad is up to its team, and that is checked against the records.
What to add to your records for CAR-T
- Target tests, if done: CD19, BCMA, or Claudin18.2 and HER2
- A list of every line of treatment: drug names, dates and the response to each
- Tests for hepatitis B and C and HIV
Send the records and we will review them free of charge, and help you see which options are worth checking with Chinese centres and what is missing. The decision to travel stays with you.
Send records for a free review
Sources: clinical guidelines, China’s drug register, FDA.
What moves the cost
CAR-T file screen
No charge to start
Antigen/line check • Approved vs trial • Centre shortlist • What the hospital will still demand
Coordinated CAR-T trip
Quoted after screen
Designated centre matching • Itemised USD/RMB drivers • Visa • Interpreter • Stay near the ward
These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.
What happens next
01
Send a CAR-T-ready file
Diagnosis, antigen data, prior lines, labs, imaging and infection status. Missing antigen testing is the most common delay.
02
Centre screen, not a package sale
We route the file to designated programmes and return a yes / no / trial / not eligible with a cost-driver range.
03
Travel after a slot is real
Apheresis, manufacturing window, lymphodepletion, infusion and monitoring are planned only after written hospital interest.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
Frequently asked questions
How much is CAR-T in China?
Navigator bands: selected public blood-cancer CAR-T sometimes from the mid five-figure USD range; private packages often about USD 70,000-90,000; satri-cel cellular product cited around RMB 990,000 before stay and ICU. ICU days change the total. Not our invoice.
Is there CAR-T for solid tumours?
Satri-cel is labelled for a narrow gastric/GEJ group after two prior lines. Other solid-tumour CAR-T needs a trial ID.
What did the Lancet satri-cel study show?
Median PFS 3.25 vs 1.77 months (HR 0.37). Grade 3 or higher adverse events 99% vs 63%. CRS in most treated patients. Modest PFS, heavy toxicity, selected patients.
How long does CAR-T take?
Collection, manufacturing and toxicity watch run to weeks. A 30-day visa-free stay is often too short.
What biomarkers do I need?
Satri-cel: CLDN18.2 positive, HER2 negative, gastric/GEJ adenocarcinoma, two prior lines. CD19/BCMA products need the labelled histology.
What records should I send?
Pathology, lines of therapy, organ function, infection status, and CLDN18.2/HER2 if gastric.
Do you hold a manufacturing slot?
No.
Do you promise a response?
No. Average reply about 24 hours. No obligation to book.
Do I pay before you read the file?
No. Payment required before a file review is a red flag. Average reply about 24 hours. No obligation to book.
How fast do you reply?
About 24 hours. We label the file as labelled care, trial, or marketing. No obligation to book.
Which CAR-T products are approved in China?
Nine CAR-T products are approved in China. Five are for B-cell lymphomas and B-cell acute lymphoblastic leukaemia, three for multiple myeloma, and one for advanced stomach cancer with Claudin18.2. Each is approved only for a defined situation, usually after several lines of treatment, so the records are reviewed first.
Can CAR-T cause a new cancer?
Yes, this risk exists. T-cell cancers have been reported after CD19- or BCMA-directed CAR-T. They can appear within weeks of the infusion and can be fatal. In 2024 the US regulator, the FDA, added this warning to the labels of these products. That is why patients are followed for life after CAR-T.
Red flags in offers
“CAR-T for any solid tumour in China.” That SKU does not exist on the label. A tourism page is not a manufacturing licence. Weeks of calendar, not a weekend infusion.
CAR-T for lung, breast, prostate with no trial ID.
No CRS warning on the sales page.
Slot promised before apheresis work-up.
Pay the product fee before a designated centre accepts the file.
Sources
NMPA / CARsgen, 22 June 2026 — satri-cel label.
Satri-cel phase 2 as reported from The Lancet.
Public descriptions of NMPA-approved CD19 and BCMA products.
Class toxicity (CRS, neurological events) in CAR-T regulator materials.
A treating haematologist or oncologist should review the file before travel. This page is matching information, not an infusion booking.
Last updated: 24 October 2026